1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,440 | 1,570 | 18:40 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS PRELIMINARY PHASE II RESULTS OF ORAL PD-L1 INHIBITOR ABSK043 COMBINED WITH EGFR ... | 1 | HKEx | ||
| 01.12. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE FDA FOR ORAL SMALL MOLECULE KRAS G12D INHIBITOR ABSK141 | 1 | HKEx | ||
| 17.11. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER STUDY OF PIMICOTINIB ... | 1 | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 03.11. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING IN A PHASE II STUDY OF ABSK043, AN ORAL SMALL-MOLECULE ... | 1 | HKEx | ||
| 27.10. | Goldman Sachs initiates Abbisko Therapeutics stock with Buy rating | 3 | Investing.com | ||
| 27.10. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTED PRECLINICAL FINDINGS ON NOVEL CDK4/2 INHIBITOR AND SMARCA2 PROTAC DEGRADER ... | 1 | HKEx | ||
| 20.10. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS PRESENTS LONGER-TERM EFFICACY AND SAFETY OUTCOMES FROM PHASE III MANEUVER TRIAL OF PIMICOTINIB ... | 1 | HKEx | ||
| 29.09. | ABBISKO-B (02256): GRANT OF OPTIONS UNDER THE POST-IPO SHARE OPTION SCHEME AND GRANT OF RSUS UNDER THE 2019 SHARE INCENTIVE PLAN | 1 | HKEx | ||
| 15.09. | ABBISKO-B (02256): 2025 INTERIM REPORT | 3 | HKEx | ||
| 28.08. | ABBISKO-B (02256): DISCLOSEABLE TRANSACTION - SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| 27.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 20.08. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE CDE FOR ABBISKO THERAPEUTICS' ORAL PD-L1 INHIBITOR ABSK043 IN COMBINATION WITH KRAS ... | 1 | HKEx | ||
| 20.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 05.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 04.08. | ABBISKO-B (02256): TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 04.08. | ABBISKO-B (02256): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
| 23.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR | 3 | HKEx | ||
| 16.07. | ABBISKO-B (02256): DATE OF BOARD MEETING | 2 | HKEx | ||
| 27.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 26.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT UPDATED RESULTS FROM THE PHASE 2 STUDY OF IRPAGRATINIB IN COMBINATION WITH ... | 1 | HKEx |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,605 | -1,34 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| IMMUNOVANT | 25,820 | +9,59 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails | ||
| AVIDITY BIOSCIENCES | 71,60 | +0,35 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| OLEMA PHARMACEUTICALS | 32,800 | +7,05 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| COGENT BIOSCIENCES | 39,760 | +1,45 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 67,49 | -2,05 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants | SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| BIONTECH | 82,00 | +0,12 % | Arrowhead, BioNTech, Madrigal & Co: Biotech-Power für das Depot! | Das Börsenjahr 2025 stand natürlich ganz klar im Schatten der US-Technologieriesen wie Nvidia & Co. Darüber hinaus sorgten auch die Gold- und Silberaktien für Aufsehen, doch eine stark laufende Branche... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 87,62 | -2,53 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis | Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported... ► Artikel lesen | |
| ARCELLX | 72,11 | +1,79 % | Stifel upgrades Arcellx stock, cites buying opportunity after share weakness | ||
| DYNE THERAPEUTICS | 19,605 | -0,38 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) | - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p - Functional improvement... ► Artikel lesen | |
| EVOTEC | 5,240 | -0,04 % | DAX-Check LIVE: Aurubis, Evotec, Formycon, Infineon, Porsche SE, Siemens Energy im Fokus | Die Erholung an der Börse hat sich zur Wochenmitte nicht fortgesetzt. Der DAX startete zwar mit kleinen Gewinnen in den Tag, rutschte im Verlauf jedoch ins Minus und schloss schließlich bei 23.694 Punkten... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 265,69 | +1,65 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 12,985 | -6,04 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting | ? Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at... ► Artikel lesen | |
| VOR BIOPHARMA | 11,490 | +11,34 % | Vor Biopharma Inc. - 8-K, Current Report | ||
| MINERALYS THERAPEUTICS | 36,660 | +1,41 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,36 % bei einem Aktienkurs von 1,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.